Fibrinolytic parameters in women undergoing ovulation induction.
OBJECTIVE
The purpose of this study was to evaluate the effect of elevated levels of circulating estradiol on the clotting and fibrinolytic system in patients undergoing controlled ovarian hyperstimulation.


METHODS
Fifty-two patients undergoing controlled ovarian hyperstimulation with human menopausal gonadotropins or urofollotropin were asked to participate. Blood for hemostasis parameters was obtained on the days that patients returned for estradiol sampling. Sample days were identified as cycle days 1 to 5 (baseline), 6 to 9, and 10 to 14. Each factor was analyzed by repeated-measures analysis of variance and correlation analysis.


RESULTS
A significant decline was observed for tissue plasminogen activator antigen and plasminogen activator inhibitor type 1 activity from baseline to cycle days 10 to 14. As serum estradiol levels increased throughout each phase (maximum mean estradiol 739.8 pg/ml), a significant linear decrease was observed for both tissue plasminogen activator antigen and plasminogen activator inhibitor type 1 activity, whereas thrombin-antithrombin III complexes did not change significantly. A significant positive correlation was also observed for plasminogen activator inhibitor activity and tissue plasminogen activator antigen level over all cycle days examined.


CONCLUSIONS
Down-regulation of the fibrinolytic system was observed as estradiol levels increased. However, thrombin formation did not change, thus suggesting that elevated circulating estradiol alone does not predispose to a thromboembolic event.
Rice
V C
VC
Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan.
Richard-Davis
G
G
Saleh
A A
AA
Ginsburg
K A
KA
Mammen
E F
EF
Moghissi
K
K
Leach
R
R
D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology*; D004958:Estradiol / Q000097:blood / Q000502:physiology*; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D010062:Ovulation Induction; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D013917:Thrombin / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000097:blood
D017395:Plasminogen Activator Inhibitor 1; D004958:Estradiol; D000990:Antithrombin III; D013917:Thrombin; D010959:Tissue Plasminogen Activator